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Background: The immunohistochemical demonstration of Enhancer of zeste homologue 2 (EZH2) proved to be a
useful marker in several tumor types. It has been described to distinguish reliably hepatocellular carcinomas from
liver adenomas and other benign hepatocellular lesions. However, no other types of malignant liver tumors were
studied so far.
Methods: To evaluate the diagnostic value of this protein in hepatic tumors we have investigated the presence of
EZH2 by immunohistochemistry in hepatocellular carcinomas and other common hepatic tumors.
EZH2 expression was examined in 44 hepatocellular carcinomas, 23 cholangiocarcinomas, 31 hepatoblastomas, 16
other childhood tumor types (rhabdomyosarcoma, neuroblastoma, Wilms’ tumor and rhabdoid tumor), 17
metastatic liver tumors 24 hepatocellular adenomas, 15 high grade dysplastic nodules, 3 biliary cystadenomas, 3
biliary hamartomas and 3 Caroli’s diseases.
Results: Most of the malignant liver tumors were positive for EZH2, but neither of the adenomas, cirrhotic/
dysplastic nodules, reactive and hamartomatous biliary ductules stained positively.
Conclusions: Our immunostainings confirm that EZH2 is a sensitive marker of hepatocellular carcinoma, but its
specificity is very low, since almost all the investigated malignant liver tumors were positive regardless of their
histogenesis. Based on these results EZH2 is a sensitive marker of malignancy in hepatic tumors. In routine surgical
pathology EZH2 could be most helpful to diagnose cholangiocarcinomas, because as far as we know this is the first
marker to distinguish transformed and reactive biliary structures. Although hepatoblastomas also express EZH2, the
diagnostic significance of this observation seems to be quite limited whereas, the structurally similar, other blastic
childhood tumors are also positive.
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The value of correct and reproducible classification of
cancers is increasing due to the more specific, occasion-
ally personalized therapeutic choices. Often, the trad-
itional hematoxylin and eosin (H&E) stained sections do
not provide enough information to make an adequate
therapeutic decision. Immunohistochemistry is still the
most widely used ancillary technique. Most of the ap-
plied antigens/antibodies can be divided into three
groups. In the biggest group, there are antigens which
are specific for cell types and they give information about
the histogenesis of tumors e.g. thyroid transcription
factor-1 (TTF-1), prostate specific antigen (PSA). In the
second group, there are antigens which help to make a
distinction between malignant and benign neoplasms e.g.
glypican 3, P53, galectin-3. The third rapidly expanding
group provides predictive information if the potential
target molecule of the therapy is present on the exam-
ined tumor sample e.g. hormone receptors, Her-2, epi-
dermal growth factor receptor (EGFR). Therefore, the
establishment of a clinically valuable diagnosis often
requires the application a battery of antibodies. Espe-
cially, when accurate diagnosis is expected from smaller
and earlier lesions the characterization and application
of novel antibodies is necessary.
Pathologists are often faced with similar problem with
specimens derived from hepatic tumors or tumor like
lesions. Hepatocellular carcinoma (HCC) is the most
common type of primary malignant liver tumor. Less dif-
ferentiated HCCs can be mistaken for biliary or meta-
static carcinomas. It also can be challenging, especially in
case of highly differentiated tumors, to distinguish these
from dysplastic nodules or hepatocellular adenomas.
Hepatocyte paraffin (Hep Par)-1 and CD 10 antibodies
stain hepatocytes and hepatocyte derived tumors in par-
affin embedded tissue [1,2]. Thus, they help to identify
the hepatocytic origin of a tumor but do not reflect
whether it is benign or malignant. In addition, they may
be negative in poorly differentiated HCC [3]. Glypican-3,
alpha-fetoprotein (AFP), heat shock protein 70 (Hsp70)
glutamine synthetase, clathrin heavy chain [3-7] anti-
bodies are reported to be distinctive for HCC, but none
of these antibodies are flawless. They are occasionally
positive in non malignant liver or in non HCC tumors
[8]. Delta like protein (DLK) is a new sensitive and spe-
cific marker, which can be used together with AFP to
diagnose hepatoblastoma [9]. Cholangiocarcinomas, (CC)
also pose difficulties in diagnosis. They are usually adeno-
carcinomas and therefore their distinction from meta-
static tumors or sometimes from HCC is a common
problem. It can also be difficult to distinguish highly dif-
ferentiated cholangiocarcinomas from ductular reactions
or biliary hamartomas. Recently αvβ6 integrin has been
reported to be a highly specific imunohistochemicalmarker for cholangiocarcinoma [10] but this antigen is
also present in reactive biliary proliferations. In summary,
the panel of antibodies available for immunohistochem-
ical diagnosis of hepatic tumors has expanded substan-
tially in the last few years. Due to focal staining patterns
and cross-reactions with other tissues, diagnostic difficul-
ties are still commonly encountered in this field, and
form the basis of the ongoing search for newer and better
immunomarkers.
Recently, enhancer of zeste homologue 2 (EZH2), a
new marker for hepatocellular carcinomas has been
described [11]. EZH2 is the catalytic subunit of polycomb
repressive complex 2 (PRC2). It catalyzes trimethylation
of lysine 27 on histone H3 (H3K27me3) and mediates
transcriptional silencing [11]. Also, EZH2 plays an im-
portant role in the maintenance of the proliferative and
self-renewal capacity of hepatic stem/progenitor cells and
their differentiation [12,13]. Cai et al. [11] reported that
this new marker was able to distinguish HCCs with high
accuracy from hepatocellular adenomas, focal nodular
hyperplasias (FNH) and dysplasic nodules. However, no
other malignant liver tumors were analyzed in this study.
EZH2 has been detected in tumors with various origins,
such as urothelial carcinoma, squamous cell carcinoma of
the esophagus, gastric cancer, glioma, renal cell carcin-
oma, non-small cell lung carcinoma (NSCLC), colorectal
carcinoma and breast cancer [14-21]. Therefore, we
decided to examine the expression of EZH2 by immuno-
histochemistry in various histological types of hepatic
tumors and tumor-like lesions to investigate its discrim-
inatory diagnostic value. EZH2 staining proved to be
positive in most of the malignant liver tumors regardless
of their origin. Thus we can confirm the result of Cai
et al. [11] that EZH2 is a sensitive marker of hepatocellu-
lar carcinomas. However, its specificity is very low, this
antibody does not help to distinguish histogenesis of dif-
ferent hepatic malignancies, since all the common types
of liver cancer stain positively for this marker.Methods
We selected 44 HCCs, 23 CCs, 31 hepatoblastomas, 16
other childhood tumors (rhabdomyosarcomas, neuro-
blastomas, Wilms’ tumors, rhabdoid tumors), 17 metasta-
ses, 24 hepatocellular-, 3 biliary adenomas, and 6 ductal
plate malformations (3 biliary microhamartomas and 3
Caroli’s disease), 15 high grade dysplastic nodules from
the archives of the Ist and the IInd Departments of Path-
ology, Semmelweis University (Budapest, Hungary). Their
clinico-pathological characteristics are summarized in
Table 1. The HCCs were graded according to Edmondson
and Steiner [22], the CCs were classified into 3 grades
[10]. The study was approved by the ethical committee of
Semmelweis University.
Table 1 Patients’ characteristics
Hepatocellular
carcinoma (n =44)
Cholangiocarcinoma
(n =23)
Age (mean) 58 58
Age (range) 42-85 30-80
Gender (male/female) 32/12 13/10
Histological grading Core/surgical Core/surgical
I. 12 8/4 5 0/5
II. 22 10/12 14 7/7
III. 9 6/3 4 3/1
IV. 1 0/1
Other tumors
Hepatoblastoma n= 31 2/29
Hepatocellular adenoma n= 24 3/21
Biliary cystadenoma n= 3 0/3
Metastatic tumor n = 17 9/8 8 colon, 2 breast,
2lung, 3neuroendocrine,
1 urothel, 1pancreas
Childhood tumors n = 16 0/16 4 rhabdomyosarcoma,
5neuroblastoma,
5 Wilms’ tumor,
2 rhabdoid tumor
Non tumorous lesions
High grade dysplastic
nodule
n = 15 0/15
Biliary hamartoma n= 3 0/3
Caroli’s disease n = 3 0/3
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the immunohistochemical reactions. Staining was per-
formed using an automated Leica Bond immunostainer,
with the Leica Bond Polymer refine detection system
and 3,3' Diaminobenzidine (DAB) as the chromogen.
Antigen retrieval was achieved with Bond Epitope Re-
trieval Solution 2 (high pH) for 20 minutes. The pri-
mary antibody was a mouse monoclonal anti-EZH2
(clone 11/EZH2) from BD Biosciences (San Jose CA,
USA) (dilution 1:100). The reaction resulted in nuclear
staining. Scores were assigned based on the density of
positivity by using negative (score = 0, no staining), weak
(score = 1, <25% of nuclei staining), moderate (score = 2,
25-75% of nuclei staining) and strong (score = 3, >75%
of nuclei staining).
Statistical analysis was performed by Fisher exact test.Results
Hepatocellular tumors and tumor like lesions
First we checked if we can reproduce the original obser-
vations of Cai et al. [11]. Forty of the examined HCCs
(n = 44) stained positively for EZH2 (Table 2). The
immunostaining always resulted in a strong nuclear re-
action and the density of positive nuclei was relatively
evenly distributed (Figure 1A). No correlation wasfound between the tumor grade, histological type and
staining scores (p = 0,7972). Background staining in the
surrounding parenchyma was only occasional, even at
low magnification, the immunostaining usually provided
clear demarcation of the tumors.
None of the hepatocellular adenomas (n = 24) reacted
with EZH2 antibody (Figure 1B), (Table 2). They have
not been subclassified but were all beta-catenin nega-
tive by immunostaining. All the investigated high grade
dysplastic nodules (n = 15) were negative for EZH2.
None of the cirrhotic nodules in 18 tumor surrounding
livers exhibited positive staining, although no macrore-
generative nodule was present in them. These results are
consistent with the original observations of Cai et al. [11].Cholangiocarcinomas, metastatic tumors and ductular
reactions
Twenty-three cholangiocarcinomas were also tested, and
all but one proved to be positive for EZH2. This included
3 highly differentiated, hilar cholangiocarcinomas (Klat-
skin tumors) (Figure 1C, D). No correlation was found
between grade and the level of expression (p = 0,8051).
The normal bile ducts and the reactive ductular reaction
either in the peritumoral tissue or in cirrhotic livers con-
sistently remained negative (Table 2). Three biliary cysta-
denomas and 6 tumor imitating ductal plate
malformations (3 biliary microhamartomas and 3 Caroli’s
disease) were also negative. Thus, this antibody appears
to be able to distinguish neoplastic and benign or react-
ive biliary proliferations. Metastatic tumors present the
major differential diagnostic problem for this tumor type.
All the investigated metastatic adenocarcinomas (from
colon, pancreas, breast and lung) were positive for EZH2
as well as the single examined transitional cell carcinoma
metastasis (Figure 2). EZH2 antibody resulted in nuclear
staining in these tumors as well and the distribution was
mostly diffuse. Only the secondary neuroendocrine
tumors (2 intestinal carcinoid tumors and 1 medullary
carcinoma of the thyroid) did not exhibit positive
staining.Hepatoblastomas and other primitive childhood tumors
Hepatoblastoma is the most common primary malignant
tumor of the liver in children. All but 2 of the investi-
gated tumors (n = 31) were positive when staining with
the EZH2 antibody (Figure 3A). The positivity was con-
fined to the epithelial part and the staining intensity and
density of the positive nuclei were usually higher in the
embryonic component.
All the other investigated primitive childhood tumors
(rhabdomyosarcomas, neuroblastomas, Wilms’ tumors
and rhabdoid tumors) stained positively for EZH2
(Figure 3B, C, D).
Table 2 EZH2 staining
EZH2 expression Negative (score0) Weak (score1) Moderate (score2) Strong (score3) Sensitivity/Specificity
Hepatocellular carcinoma (n = 44) 0.90/0.33
Grade I. 2 6 4 0
Grade II. 1 12 7 2
Grade III 1 4 2 2
Grade IV. 0 1 0 0
CC (n = 23) 0.96/0.18
Grade I. 0 2 2 1
Grade II. 1 2 9 2
Grade III 0 1 3 0
Hepatoblastoma (n = 31) 2 6 9 14 0.94/0.24
Hepatocellular adenoma (n = 24) 24 0 0 0 0/0
Biliary cystadenoma (n = 3) 3 0 0 0 0/0
Metastases NC*
Colon (n = 8) 0 0 5 3
Breast (n = 2) 0 0 2 0
Lung (n = 2) 0 0 0 2
Neuroendocrine (n = 3) 3 0 0 0
Urothel (n = 1) 1
Pancreas (n = 1) 1
Childhood tumors NC*
Rhabdomyosarcoma (n = 4) 0 1 2 1
Neuroblastoma (n = 5) 0 0 3 2
Wilms’ tumor (n = 5) 0 1 1 3
Rhabdoid tumor (n = 2) 0 0 1 1
Non tumorous lesions
High grade dysplastic nodule (n = 15) 15 0 0 0
Biliary hamartoma (n = 3) 3 0 0 0
Caroli’s disease (n = 3) 3 0 0 0
*NC not counted due to low case number.
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In this study, we report that EZH2 was detected by
immunohistochemistry in nearly all the investigated
HCCs, CCs, hepatoblastomas, metastatic liver tumors
and several other childhood cancers. However, none of
the hepatocellular or biliary adenomas, high grade dys-
plastic or cirrhotic nodules was positive. The ductular
reactions and biliary hamartomas were also consistently
negative.
Knockdown of EZH2 reversed the tumorigenicity in
experimental liver tumors, suggesting that EZH2 plays
an important role in HCC tumorigenesis [23,24].
Increased expression of EZH2 was correlated with un-
favourable outcome of HCC [25] and metastatic capacity
[26]. Cai et al. [11] demonstrated convincingly that
EZH2 is a highly sensitive diagnostic biomarker of HCC,
which can be used to distinguish it from benign liver
lesions such as hepatocellular adenomas, focal nodularhyperplasias, dysplastic and regenerative nodules. There
is a complete agreement between the findings of Cai et
al’s [11] and our study that all the investigated regenera-
tive nodules and adenomas were negative. Our results
also support that EZH2 is a sensitive marker of HCC. Al-
though not reaching statistical significance, EZH2
appeared less able to recognize well differentiated HCCs
in both studies. There seems to be a borderline or “grey
zone” in highly differentiated hepatocellular tumors, in
which EZH2 similarly to the other markers, is not abso-
lutely reliable. It requires further direct comparative
studies, which one of the recently applied markers (Gly-
pican3, AFP, Hsp70, EZH2) is the most sensitive [3-7].
Most likely however, a panel of these antibodies would
provide the most trustworthy information and EZH2
could be a useful member of this battery. All of the ad-
enomas in our study were beta-catenin negative. The
beta-catenin status of the adenomas in the study of Cai
Figure 1 EZH2 staining in primary liver tumors. A/HCC, nuclear staining in tumor cells, the surrounding liver is negative;
B/hepatocellular adenoma, there is no staining; C/CCC, note the unstained nuclei of the non tumorous bile duct in the center¸
D/positively stained highly differentiated CCC (Klatskin tumour). Scale bar for the Figure 1:50 μm.
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examine EZH2 expression in beta-catenin positive hepa-
tocellular adenomas, which have a higher tendency for
malignant transformation [27].
In addition to hepatocellular lesions, there are other
hepatic tumors, which may raise differential diagnostic
problems. For this reason we investigated EZH2 expres-
sion in the most common other tumor types of liver.
EZH2 staining was positive in 96% of cholangiocarcino-
mas, including 3 highly differentiated Klatskin tumors.Figure 2 EZH-2 staining in metastatic liver tumors. A/neuroendocrine
the nuclei of B/colon; C/breast and D/transitional cell carcinoma metaAs far as we know EZH2 expression has not previously
been examined in this type of tumor. We have studied a
few biliary cystadenomas and tumor mimicking ductal
plate malformations, all of them were negative, as well as
the ductular reactions. CC also must be differentiated
from metastatic liver tumors. Practically all the meta-
static adenocarcinomas, regardless of their origin, were
positive for EZH2. Although our case number is low, the
primary tumors of colon, pancreas, breast, lung [14-21]
have already been described to express this tumorcarcinoma from the ileum is negative; while positive reaction in
stases. Scale bar for the Figure 2: 50 μm.
Figure 3 EZH-2 staining in childhood tumors. A/hepatoblastoma, the stroma is negative, weak nuclear staining in fetal and strong
reaction in the embryonal areas. B/Wilms’ tumor; C/embryonal rhabdomyosarcoma; D/neuroblastoma. Scale bar for the Figure 3: 50 μm.
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flect reality. That is, EZH2 similarly to other CC markers
e.g. CK7, CK19, claudin 4 [28] does not provide major
help in distinguishing cholangiocarcinomas from meta-
static tumors, but it does seem to be able to differentiate
reactive/hamartomatous biliary structures and benign
biliary tumors from malignant ones. This is important
because so far no such marker has been reported. Even
the recently described highly specific cholangiocarci-
noma marker, αvβ6 integrin [10] is positive in proliferat-
ing bile ducts. The combination of these two antibodies
may facilitate the diagnosis of cholangiocarcinomas.
EZH2 expression has not yet been tested on hepato-
blastomas and other primitive "blastic" tumors except
Ewing’s sarcoma and rhabdoid tumors which were
reported positive [29,30]. The applied antibody recog-
nizes these tumors with high sensitivity. All but two of
the examined hepatoblastomas (n = 31) and the few other
childhood tumors stained positively. This is not surpris-
ing, as it is considered that the major biological function
of EZH2 is to maintain the undifferentiated stage of cells
[31]. Again, the number of non hepatoblastomas investi-
gated is quite low, but considering the very consistent
positive staining it is highly unlikely that EZH2 could be
used to differentiate among these childhood tumors.
However, if recent therapeutic approaches targeting
EZH2 [32] were successful, our observation in childhood
tumors would gain significance.
Conclusions
In conclusion, we can confirm the recent report of Cai
et al. [11] that EZH2 is a reliable immune marker forhepatocellular carcinomas, compared to non-malignant
hepatocellular lesions. EZH2 is not however, specific for
HCC since almost all other examined hepatic cancers:
cholangiocarcinomas, hepatoblastomas and metastatic
adenocarcinomas are positive as well. Consequently, this
marker does not provide help in differentiating the spe-
cific histogenesis of liver tumors, but it may well be very
useful to differentiate malignant hepatocellular and cho-
langiocellular tumors from benign tumors and reactive
lesions. As far as we know EZH2 is the first marker,
which is able to do this for biliary cells derived lesions.
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